Oct

6

2021

What is caplacizumab?

By William Aird

A humanized anti-von Willebrand factor (vWF) single-variable-domain immunoglobulin (nanobody) that targets AI domain of vWF, preventing its interaction with platelet glycoprotein 1b-IX-V, FDA approved for treatment of adults with immune TTP in combination with plasma exchange and immunosuppressive therapy.